Personalis Quick Ratio 2018-2026 | PSNL
Historical quick ratio values for Personalis (PSNL) over the last 10 years.
| Personalis Quick Ratio Historical Data | |||
|---|---|---|---|
| Date | Current Assets - Inventory | Current Liabilities | Quick Ratio |
| 2026-03-31 | $0.25B | $0.04B | 6.44 |
| 2025-12-31 | $0.26B | $0.04B | 6.61 |
| 2025-09-30 | $0.17B | $0.04B | 4.70 |
| 2025-06-30 | $0.19B | $0.03B | 5.92 |
| 2025-03-31 | $0.20B | $0.03B | 6.74 |
| 2024-12-31 | $0.20B | $0.03B | 6.33 |
| 2024-09-30 | $0.16B | $0.04B | 4.44 |
| 2024-06-30 | $0.10B | $0.03B | 3.05 |
| 2024-03-31 | $0.11B | $0.03B | 3.56 |
| 2023-12-31 | $0.14B | $0.05B | 2.89 |
| 2023-09-30 | $0.14B | $0.03B | 4.31 |
| 2023-06-30 | $0.15B | $0.03B | 5.35 |
| 2023-03-31 | $0.18B | $0.03B | 5.11 |
| 2022-12-31 | $0.19B | $0.03B | 5.77 |
| 2022-09-30 | $0.21B | $0.03B | 6.35 |
| 2022-06-30 | $0.25B | $0.04B | 6.08 |
| 2022-03-31 | $0.29B | $0.04B | 7.18 |
| 2021-12-31 | $0.31B | $0.03B | 9.98 |
| 2021-09-30 | $0.32B | $0.03B | 12.20 |
| 2021-06-30 | $0.35B | $0.03B | 10.18 |
| 2021-03-31 | $0.37B | $0.04B | 9.52 |
| 2020-12-31 | $0.22B | $0.04B | 5.29 |
| 2020-09-30 | $0.22B | $0.04B | 6.05 |
| 2020-06-30 | $0.11B | $0.04B | 2.64 |
| 2020-03-31 | $0.13B | $0.05B | 2.48 |
| 2019-12-31 | $0.14B | $0.05B | 2.70 |
| 2019-09-30 | $0.14B | $0.05B | 2.86 |
| 2019-06-30 | $0.17B | $0.06B | 3.06 |
| 2019-03-31 | $0.00B | 0.00 | |
| 2018-12-31 | $0.00B | 0.00 | |
| 2018-09-30 | $0.00B | 0.00 | |
| 2018-06-30 | $0.00B | 0.00 | |
| 2017-12-31 | $0.00B | 0.00 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.630B | $0.070B |
| Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |